This report provides policy recommendations to help deliver safer and cheaper medical products to people suffering from neglected diseases in developing countries, where they are needed the most.

Although more drugs and vaccines are reaching late-stage clinical development, says the report, they are held back by a lack of funding to support clinical trials, as well as clinical research and regulatory capacity in settings where neglected diseases are endemic. This undermines safety and the validity of clinical data.

The report recommends a two-pronged approach to improving the quality and regulation of clinical trials in the developing world: establishing regional regulatory pathways for the oversight of clinical trials, and building quality and cost-efficiency into trial design and implementation. It also recommends practical steps that can be taken by donors, drug and vaccine developers, and regulatory authorities to begin implementing the changes.

In this review article, published after the Fukushima accident, medical scientists examine published information on the short- and long-term health risks of exposure to ionising radiation. The article describes two previous nuclear accidents — at Three Mile Island in the USA, and Chernobyl in Ukraine — and explains the types and doses of radiation that can damage biological systems. It discusses the mechanisms behind exposure, and radiation-induced illness and injury, including long-term cancer risks. The authors also review measures that can be taken to reduce the effects of radiation exposure, including potassium iodide tablets used in the aftermath of Chernobyl. The article stresses that clear communication on radiation exposure levels and health risks is a key component of the response to a nuclear incident.

This paper discusses how researchers promote the use of research in policy by examining the practices of 'boundary organisations' that cross the boundary between science and politics to facilitate evidence-based policies and programmes. It identifies key lessons for organisations looking to engage policymakers and decision-makers.

The study focuses on the Regional Network on AIDS, Livelihoods and Food Security (RENEWAL), a regional 'network of networks' active in Kenya, South Africa, Uganda, and Zambia which engages government officials on programmes that could inform policies on food, nutrition and HIV/AIDS. It describes the challenges and successes of efforts to promote research in these areas; challenges include adherence to scientific principles while maintaining close relationships with political authority, and ensuring accountability to the communities within which the research is conducted.

The paper offers recommendations to strengthen efforts to get research into policy, and concludes that the concept of a boundary organisation can help researchers engage people and processes that have decision-making power.

This peer-reviewed report, from the UK Department for International Development (DFID), summarises current evidence on malaria, covering topics that range from epidemiology to public health interventions, disease management and elimination. It focuses on areas where policy or practical decisions have to be made, mainly by DFID and its development partners.

The paper is divided into sections that provide an overview of issues such as determinants of infection, high-risk groups, artemisinin and insecticide resistance, and interventions such as vector control. These correspond to areas relevant to decision making, with the report being a 'portal' to more detailed information rather than a definitive document. Because many of the issues addressed are context-specific, the paper should be read in conjunction with country profiles published by DFID as well as country-specific data available in the World Malaria Report.

This special issue of the journal Philosophical Transactions of the Royal Society B: Biological Science explores how vaccines can fulfil their full potential for addressing global health challenges. It charts the progress to date, reviewing successes as well as challenges in the development and distribution of both human and veterinary vaccines.

The articles describe how vaccines can help mitigate and treat the world's major infectious diseases such as malaria, tuberculosis and HIV/AIDS, as well as chronic diseases, such as cancer. They explore vaccine policy and financing, ways to accelerate the development of new vaccines, issues surrounding public acceptance, and the logistics of getting vaccines to where they are needed. Also discussed is the use of vaccines to treat diseases in livestock — making an important link between health interventions, agricultural output and economic consequences.

The papers in this issue were presented at the meeting, 'New vaccines for global health', held at the Royal Society in London, United Kingdom, in November 2010.

This report, from medical aid organisation Médecins Sans Frontières, explores the impact of and lessons learned from the use of antiretroviral treatment (ART) for HIV/AIDS since 2000, when it began providing this to people in need of urgent treatment. It presents results of a survey conducted in 16 countries with different prevalence levels of the disease, which together account for 52.5 per cent of the global HIV/AIDS burden, and outlines the progress, strengths and weaknesses of the international response to the disease.

The report provides an overview of key treatment strategies to improve care and reduce its cost for patients and health systems; discusses the impact of decreased donor funding; and suggests policies that can help lower drug costs, for example, or foster innovations for more effective and affordable treatment. Most HIV-prevalent countries still lack the capacity to treat more than 50 per cent of their population in need of ART, or to provide ART in more than 50 per cent of existing facilities — underlining the need for more domestic and external resources.

This report examines the threat posed by non-communicable diseases in low- and middle-income countries, which carry nearly 80 per cent of the world's burden of cardiovascular disease; diabetes; cancer; obesity; and chronic respiratory disease. It includes tables and maps of global, regional and country-specific trends including estimated mortality rates. The data are also used to predict future trends and assess factors contributing to non-communicable disease.

Drawing on what developed countries have learned about these diseases, the report outlines options for tackling them, such as early detection and treatment. To encourage immediate action, it puts forward a series of highly cost-effective solutions that are affordable even where resources are limited. It also emphasises the need for strong health-care systems, improved surveillance and monitoring, and nongovernmental and civil society participation in efforts to reduce the burden of non-communicable disease.

This paper, co-authored by Paul Newton of the Mahosot Hospital in Laos — who has collaborated closely with INTERPOL in its anti-counterfeiting operations — summarises evidence on the prevalence of counterfeit drugs, and details their medical and economic impact on poor countries. It outlines how the international community can tackle the problem, which the authors say needs to be taken more seriously. Although the trade in counterfeit drugs has obvious health impacts, its indirect effects are no less significant and include a loss of confidence in health systems and health workers.

This study documents the chemical composition of drugs randomly sampled from pharmacies in Delhi and Chennai in India, and aims to offer the government guidance on improving drug regulation. India is a major producer and consumer of pharmaceuticals but, with quality control standards varying significantly between states, the country has high levels of counterfeit drugs. The study shows that 12 per cent of Delhi samples and 5 per cent of Chennai samples collected in 2008 and 2009 did not meet international quality standards. Although these numbers roughly match the government's estimates, there were differences between pharmacies in the types of drugs commonly counterfeited. And while some had no fake drugs, others had up to 30 per cent.

This document from the Medicines Transparency Alliance — founded by the World Bank, the WHO and the UK Department for International Development (DFID) — gives an account of a pilot programme that  investigated the medicines supply chain to identify problems that prevent vulnerable people from accessing essential medicines. It presents findings from Ghana, Jordan, Kyrgyzstan, Peru, the Philippines, Uganda and Zambia. The programme relied on different stakeholders from government, civil society and the private sector to collect, share and analyse data. The evidence gathered through the project was used to inform policy in these countries.

This toolkit from the World Health Professions Alliance (WHPA) — an alliance of organisations representing more than 25 million healthcare professionals worldwide — aims to educate staff and patients about counterfeit medicines. It was commissioned by the WHO's International Medical Products Anti-Counterfeiting Task Force (IMPACT). The toolkit includes a form that healthcare workers can use to report on suspected counterfeit medicines and a visual inspection checklist that can be used to judge whether or not a medicine might be fake. It also offers useful advice on how health professionals can answer media questions, how to communicate concerns to patients and how to educate the public on the dangers of counterfeit drugs.

This briefing paper, aimed at policymakers and researchers, discusses the regulatory implications of having varied definitions of the term 'counterfeit' and outlines successful law enforcement initiatives to halt the trade in fake drugs. The paper outlines the problem of counterfeit medicines and the urgent issues to be considered by the international community before taking additional steps to tackle it. It discusses the controversy around intellectual property rights and counterfeits, and investigates the motives behind some anti-counterfeiting initiatives that seem to be more concerned with protecting patents.

This report, published by the WHO, collates data obtained over 8 years by WHO assessment teams working in 26 African countries. The teams analysed different aspects of national regulatory systems such as management, funding and quality control procedures. Poor regulatory systems in impoverished nations are often blamed for allowing the spread of counterfeit drugs in the developing world.  The report says that although mechanisms for drug regulation existed in every country, and there were guidelines for quality-control inspections, these were often not well executed because of a severe lack of resources and staff.

This report makes a case for the importance of antimalarial drug monitoring as an integral part of disease surveillance programmes in developing countries. Antimalarials are some of the most commonly counterfeited drugs — the high prevalence of malaria translates to a large consumer market in the developing world. The problem is serious in South-East Asia but is expected to become significant in African countries too. The report suggests that scientists ensure drugs are genuine and of a good quality before conducting efficacy or resistance studies in areas where counterfeits circulate widely.

This report explores the role of agricultural growth in reducing and preventing undernutrition — deficiencies in energy, protein, and essential vitamins and minerals.

It describes how agricultural growth increases the capacity of households to produce more nutritious food and to buy more nutritious food by boosting income levels. Agricultural growth also improves nutrition through a broader effect on the economy, such as increasing government revenues to fund education, health, infrastructure, and nutrition intervention programmes.

The report gives an overview of the relationship between nutrition and growth, examines different growth patterns and their nutritional outcomes, and identifies factors that influence this dynamic — such as a country's stage of economic development.

A new paradigm for agricultural development is needed, says the report, where agricultural growth leads not only to increased production and reduced poverty, but also to improved nutrition. It concludes with recommendations for future research, and aims to provide policymakers with knowledge about development and investment strategies that can improve nutritional outcomes.

The Center is a US-based think tank that aims to help decision-makers innovatively address global health issues through multidisciplinary research. Key projects include developing policy proposals to deal with antibiotic resistance in low- and middle-income countries, and a financing mechanism to increase access to affordable malaria therapies. The website features a blog, lists details of projects, and includes links to relevant presentations and publications.

This report presents evidence that people with mental health conditions meet major criteria for vulnerability and should be targeted for protection by development programmes. Mental illness such as schizophrenia, depression or bipolar disorder are common but largely neglected.

The WHO makes the case that because of their vulnerability, people with mental health problems need to be given opportunities for education and work, and to be included in decisions that affect them.

It argues that mental health should be built into sectoral and broader plans for development, with government agencies, NGOs and other stakeholders playing a key role in ensuring this. To make implementation a reality, interventions and mainstreaming efforts should be funded adequately, and recipients of development aid should be encouraged to address the needs of people with mental health conditions. The report recommends actions as a starting point towards these aims.

This opinion article argues that excessive concern about the risks of nanotechnology in developing countries could derail its progress and hinder the enormous health, environment and economic benefits to be gained from nanotechnology research. The authors identify the developing countries making the most advances in nanotechnology, those in the middle ground, and the "up and comers".

This report from PLoS Medicine argues that nanotechnology has a role in the development of low-income countries. The authors survey 85 experts worldwide and rank the top ten nanotech applications most likely to benefit developing nations. They outline how these applications can help meet the Millennium Development Goals. The paper calls for an initiative to identify "grand challenges" in nanotechnology for global health, which since the publication of this paper are now underway.

This follow-up paper, from the Journal of Nanotechnology Online, provides an in-depth look at the way poor countries engage with nanotechnology. It analyses why some developing nations are ahead of others in nanotechnology progress, and the challenges some less-developed countries face in shoring up nanotechnology capacity. It also investigates nanotechnology patent activity and assesses country participation in nanotechnology policy dialogues – for instance, China is a frontrunner in filing nanotech patents yet it is absent from policy discussions.